DrugPatentWatch Database Preview
Kai Pharms Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for KAI PHARMS INC, and what generic alternatives to KAI PHARMS INC drugs are available?
KAI PHARMS INC has one approved drug.
There are six US patents protecting KAI PHARMS INC drugs.
There are seventy-five patent family members on KAI PHARMS INC drugs in forty-one countries and twelve supplementary protection certificates in eleven countries.
Summary for Kai Pharms Inc
| International Patents: | 75 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Kai Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-001 | Feb 7, 2017 | RX | Yes | Yes | 9,701,712 | Start Trial | Y | Y | Start Trial | ||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-001 | Feb 7, 2017 | RX | Yes | Yes | 9,278,995 | Start Trial | Y | Start Trial | |||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | 10,344,765 | Start Trial | Y | Start Trial | |||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | 9,278,995 | Start Trial | Y | Start Trial | |||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | 8,999,932 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Kai Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2014302122 | Start Trial |
| Serbia | 56238 | Start Trial |
| Singapore | 11201510647T | Start Trial |
| South Africa | 201600238 | Start Trial |
| Turkey | 201907941 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Kai Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2459208 | 300864 | Netherlands | Start Trial | PRODUCT NAME: ETELCALCETIDE OF EEN ZOUT DAARVAN, MET INBEGRIP VAN ETELCALCETIDEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1142/001-012 20161115 |
| 2459208 | CA 2017 00006 | Denmark | Start Trial | PRODUCT NAME: ETELCALCETID ELLER ET SALT DERAF, INKLUSIV ETELCALCETIDHYDROCHLORID; REG. NO/DATE: EU/1/16/1142/001-012 20161115 |
| 2459208 | PA2017007 | Lithuania | Start Trial | PRODUCT NAME: ETELKALCETIDAS ARBA JO DRUSKA, ISKAITANT ETELKALCETIDO HIDROCHLORIDA; REGISTRATION NO/DATE: EU/1/16/1142 20161111 |
| 2459208 | CR 2017 00006 | Denmark | Start Trial | PRODUCT NAME: ETELCALCETID ELLER ET SALT DERAF, INKLUSIV ETELCALCETIDHYDROCHLORID; REG. NO/DATE: EU/1/16/1142/001-012 20161115 |
| 2459208 | C02459208/01 | Switzerland | Start Trial | PRODUCT NAME: ETELCALCETID; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66338 27.09.2017 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
